{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:11:30Z","timestamp":1750219890029,"version":"3.41.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":75,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100508","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:37:53Z","timestamp":1742319473000},"page":"100508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tyrosine kinase inhibitors modulate the expression of peroxiredoxins 1 and 2 in chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3258-1132","authenticated-orcid":false,"given":"Hiroshi","family":"Kazama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2025.100508_bib0001","doi-asserted-by":"crossref","first-page":"24273","DOI":"10.1074\/jbc.M002094200","article-title":"The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells","volume":"275","author":"Sattler","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lrr.2025.100508_bib0002","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/ars.2011.4258","article-title":"Redox control of leukemia: from molecular mechanisms to therapeutic opportunities","volume":"18","author":"Irwin","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.lrr.2025.100508_bib0003","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1101\/gad.11.19.2456","article-title":"The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-abl tyrosine kinase activity","volume":"11","author":"Wen","year":"1997","journal-title":"Genes Dev."},{"key":"10.1016\/j.lrr.2025.100508_bib0004","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.12954","article-title":"Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia","volume":"166","author":"Kazama","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2025.100508_bib0005","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1182\/blood-2011-06-358705","article-title":"Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene","volume":"119","author":"Agrawal-Singh","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100508_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3164\/jcbn.11-109","article-title":"Novel roles of peroxiredoxins in inflammation, cancer and innate immunity","volume":"50","author":"Ishii","year":"2012","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.lrr.2025.100508_bib0007","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100508_bib0008","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2012.11.003","article-title":"Imatinib and nilotinib inhibit bcr-abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox","volume":"37","author":"Landry","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.lrr.2025.100508_bib0009","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1002\/jcb.26686","article-title":"Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells","volume":"119","author":"Damiano","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.lrr.2025.100508_bib0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12935-021-02064-x","article-title":"Integrative analysis the characterization of peroxiredoxins in pan-cancer","volume":"21","author":"Gao","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.lrr.2025.100508_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100678","article-title":"Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies","volume":"44","author":"Tanaka","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.lrr.2025.100508_bib0012","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/pharmaceutics15030917","article-title":"Immunomodulatory activity of the tyrosine kinase inhibitor dasatinib to elicit NK cytotoxicity against cancer, HIV infection and aging","volume":"15","author":"Rodr\u00edguez-Agust\u00edn","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lrr.2025.100508_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/2326-6066.CIR-20-1023","article-title":"PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress","volume":"10","author":"Klopotowska","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lrr.2025.100508_bib0014","first-page":"1081","article-title":"The post-translational modification, SUMOylation, and cancer (Review)","volume":"52","author":"Han","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lrr.2025.100508_bib0015","doi-asserted-by":"crossref","first-page":"10840","DOI":"10.3748\/wjg.v21.i38.10840","article-title":"Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer","volume":"21","author":"Sun","year":"2015","journal-title":"World J. Gastroenterol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892500010X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892500010X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:15:13Z","timestamp":1750180513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221304892500010X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"alternative-id":["S221304892500010X"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100508","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine kinase inhibitors modulate the expression of peroxiredoxins 1 and 2 in chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100508"}}